 |
138 Diseases |  |
94 Trials |
|
94 Trials |  |
2090 News |  |
| «12345678910111213...3233» |
- leuprolide acetate for depot suspension / Generic mfg.
Clinical outcomes with leuprolide acetate for the treatment of recurrent granulosa cell tumor () - Feb 1, 2023 - Abstract #SGO2023SGO_204;
- ||| leuprolide acetate for depot suspension / Generic mfg.
Clinical, Adverse events: We invited patients to share their experiences with Lupron. It’s mind boggling to see how their lives are impacted by the side effects. Many didn’t even know these side effects existed when started lupron. https://t.co/HB5LxfL7GO (Twitter) - Jan 31, 2023
- ||||| leuprolide acetate for depot suspension / Generic mfg.
Clinical: A patient was billed $73 800 at the University of Chicago for 2 injections of Lupron depot, a treatment for prostate cancer, a drug available in the UK for $260 a dose https://t.co/FcqTe1J6ID (Twitter) - Jan 30, 2023
- || leuprolide acetate for depot suspension / Generic mfg.
We start ADT/RT around the same time, no dogma. I usually give Lupron at sim. (Twitter) - Jan 27, 2023
- |||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas
New trial, HEOR, Real-world evidence, Real-world, Metastases: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov) - Jan 26, 2023
P=N/A, N=15000, Not yet recruiting, Sponsor: Pfizer
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P4 trial: ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) - Jan 26, 2023
P4, N=228, Not yet recruiting, Sponsor: University of Colorado, Denver
- ||||||| Kisqali (ribociclib) / Novartis
Trial completion, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Jan 25, 2023
P3, N=3246, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed
- | Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer. (Pubmed Central) - Jan 20, 2023
While the analysis revealed a slight chance of sustaining testosterone suppression with relugolix, ADT with relugolix provided no significant survival advantages over ADT with leuprolide. Therefore, this analysis confirms no need for further assessment of APC interventions to make informed decisions beneficial to the APC patients, oncologists, and other stakeholders.
- || leuprolide acetate for depot suspension / Generic mfg.
پيشرفته، Leuprorelin acetate به صورت تزريق زيرپوستي با دوز معمولي يك ميليگرم در روز تجويز ميشود. واکسیناسون کرونا در خیلی از کشورها به ظور کامل تمام شده @merck #cancer (Twitter) - Jan 19, 2023
- | Truqap (capivasertib) / Otsuka, AstraZeneca
Trial initiation date, Combination therapy: SNARE: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (clinicaltrials.gov) - Jan 19, 2023
P2, N=30, Not yet recruiting, Sponsor: VA Office of Research and Development
Therefore, this analysis confirms no need for further assessment of APC interventions to make informed decisions beneficial to the APC patients, oncologists, and other stakeholders. Initiation date: Jan 2023 --> Apr 2023
- | tamoxifen / Generic mfg.
Trial primary completion date: ASPAIT: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women (clinicaltrials.gov) - Jan 17, 2023
P3, N=680, Recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
Initiation date: Jan 2023 --> Apr 2023 Trial primary completion date: Dec 2020 --> Dec 2023
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Trial initiation date, Trial primary completion date: NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (clinicaltrials.gov) - Jan 17, 2023
P2, N=32, Not yet recruiting, Sponsor: Rana McKay, MD
Trial primary completion date: Dec 2020 --> Dec 2023 Trial completion date: Jul 2024 --> Dec 2024 | Initiation date: Dec 2022 --> Jul 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
- || leuprolide acetate for depot suspension / Generic mfg.
MRI!!! While doing it, REI consult (does she have/want frozen eggs/ embryos) and other concerns then put it all together. Lupron preop may not work well if pedunculated. I recently had a case like this. (Twitter) - Jan 16, 2023
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Influence of encapsulation variables on formation of leuprolide-loaded PLGA microspheres. (Pubmed Central) - Jan 15, 2023
The increased viscosity of the primary emulsion, decreased secondary water phase volume and reduced second homogenization time each elevated encapsulation efficiency of peptide by reducing drug leakage to the outer water phase. These results could be useful for dimensional analysis and improving manufacturing of PLGA microspheres by the solvent evaporation method.
- ||| Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Journal, Adverse events: Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. (Pubmed Central) - Jan 15, 2023
Real-life data suggest GnRH agonists are associated with higher CV AEs when compared to GnRH antagonists. Clinicians should consider these data when prescribing HT especially in patients with CV comorbidities.
- | Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds. (Pubmed Central) - Jan 12, 2023
These enzymes could, in principle, activate the amide bond via reductive or oxidative metabolism outside the amide bond. The identity of the involved drug metabolizing enzymes in this process is still unknown.
- leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg.
De novo prostate cancer in renal transplant recipients: A single-center study. (On Demand | Level 1, West Hall; Poster Board No. L4) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_386;
Most of our RTRs with PC had early-stage disease with excellent 5-year survival. The current standard-of-care treatment modalities for PC appear to be effective in the management of these patients.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database. (On Demand | Level 1, West Hall; Poster Board No. C4) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_235;
The percentage of combination therapy with PC medications was higher for relugolix users than it was for leuprolide users. These results provide insight into the real-world use of relugolix in combination with other PC medications.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX. (On Demand | Level 1, West Hall; Poster Board No. R2) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_186;
P=N/A
In addition to assessing routine clinical care and disease progression, patient reported outcomes will be assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) for HRQoL and Simplified Medication Adherence Questionnaire (SMAQ) for adherence at 3 and 6 months then every 6 months. Clinical trial information: NCT05467176.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN). (On Demand | Level 1, West Hall; Poster Board No. Q5) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_170;
P2
We also aim to determine adverse event rates for both treatment arms and evaluate genomic and blood markers of treatment response. This study opened in December 2021.
- | leuprolide acetate for depot suspension / Generic mfg.
Preclinical, Journal: Chronic periadolescent leuprolide exposure affects the development of reproductive physiology and behavior of female and male rats differently, but both mature after treatment termination. (Pubmed Central) - Jan 8, 2023
Nevertheless, not long after leuprolide treatment is discontinued, sex-typical reproductive physiology and behavior emerge fully in female and male rats, indicating that the drug's effects are not permanent. If translatable to humans, leuprolide may be a reversible option to give adolescents more time to consider their gender identity with minimal long-term effects on sexual development.
- Firmagon (degarelix) / Astellas, Ferring
CARDIOVASCULAR OUTCOMES ASSOCIATED WITH DEGARELIX VERSUS LEUPROLIDE FOR PROSTATE CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_7515;
In men with prostate cancer, degarelix was not inferior to leuprolide in terms of risk for adverse cardiovascular outcomes. These findings align with the largest clinical trial (The PRONOUNCE Trail) to date.
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Clicks away from reduced healthcare expenditures: leveraging the electronic health record to reinforce education efforts. (Pubmed Central) - Jan 4, 2023
These findings align with the largest clinical trial (The PRONOUNCE Trail) to date. This report adds to the body of evidence that leveraging the EHR can lead to healthcare savings and illustrates how patient and healthcare system burden can be reduced by prompting thought and direction when a medication has indication specific dose requirements.
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study. (Pubmed Central) - Jan 3, 2023
An LA 3-month depot was equally effective and safe as a 1-month depot for hormonal suppression and bone maturation inhibition, providing clinical experience in China. The 11.25 mg depot of LA is a safe, efficient, and economical treatment method for the advanced activation of the hypothalamic-pituitary-gonadal (HPG) axis.
- | leuprolide acetate for depot suspension / Generic mfg.
New trial: A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT (clinicaltrials.gov) - Dec 28, 2022
P=N/A, N=200, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- || leuprolide acetate for depot suspension / Generic mfg.
PK/PD data, Preclinical, Journal: Determination of Leuprolide-Fatty Acid Conjugate in Rat Plasma Using LC-MS/MS and Its Pharmacokinetics after Subcutaneous Administration in Rats. (Pubmed Central) - Dec 24, 2022
After the subcutaneous administration of fatty-acid-conjugated leuprolide, the mean absorption time and half-life were prolonged. To the best of our knowledge, this is the first study showing the effects of fatty acid conjugates on the pharmacokinetics of leuprolide using a newly developed UPLC-MS/MS method for the simultaneous quantification of leuprolide and LOCs.
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Effects of social rank and pubertal delay on brain structure in female rhesus macaques. (Pubmed Central) - Dec 19, 2022
But, even more importantly, they indicate different brain structural effects of chronological age and pubertal developmental stage in females, which are very difficult to disentangle in human studies. These findings have additional relevance for young girls who experience prolonged pubertal delays or for those whose puberty is clinically arrested by pharmacological administration of Lupron.
- | leuprolide acetate for depot suspension / Generic mfg., anastrozole / Generic mfg., testosterone gel / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Regulation of Cortisol Metabolism and Fat Patterning (clinicaltrials.gov) - Dec 16, 2022
P=N/A, N=140, Active, not recruiting, Sponsor: Oregon Health and Science University
These findings have additional relevance for young girls who experience prolonged pubertal delays or for those whose puberty is clinically arrested by pharmacological administration of Lupron. Unknown status --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2024 | Trial primary completion date: Mar 2020 --> Mar 2024
- |||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open, Adverse events: REPLACE-CV: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (clinicaltrials.gov) - Dec 14, 2022
P3, N=2250, Recruiting, Sponsor: Myovant Sciences GmbH
Unknown status --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2024 | Trial primary completion date: Mar 2020 --> Mar 2024 Not yet recruiting --> Recruiting
- || leuprolide acetate for depot suspension / Generic mfg.
Many trends like this of uro-rads groups used mostly IMRT back when it paid high rates instead of RP, or giving tons of ADT mono back when lupron paid major $$. All of these practices are likely inappropriate and non evidence based. Some proved even to be harmful (ADT mono). (Twitter) - Dec 9, 2022
- | Trial completion date, Trial primary completion date, Metastases: A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy (clinicaltrials.gov) - Dec 7, 2022
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Recruiting Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2023 --> Oct 2022
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Case - Leuprolide acetate-induced necrotic skin ulceration. (Pubmed Central) - Dec 7, 2022
Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2023 --> Oct 2022 No abstract available
- ||||| enzalutamide capsule / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Clinical, Monotherapy: The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDI3mW @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open (Twitter) - Dec 6, 2022
- | Journal, Real-world evidence: Real-world prescription patterns for reproductive assistance patients in China: A trend analysis from 2016 to 2020. (Pubmed Central) - Dec 6, 2022
Different progesterone preparations (47472, 21.08%), chorionic gonadotrophin gondotrophin for injection (38932, 17.29%), dydrogesterone tables (33591, 14.91%), and triptorelin for injection (26959, 11.97%) rounded out the top five...Goserelin, leuprorelin, triptorelin, growth hormone, and didroxyprogesterone are among the top five most expensive medications per capita...In addition, the price of certain medicines is high, which will increase the patients' financial burden. Future research will focus on enhancing the degree of rational drug use among outpatients and realizing the economical, safe, and effective use of pharmaceuticals to lessen the economic burden of patients.
- ||||| leuprolide acetate for depot suspension / Generic mfg.
Pricing: Can someone from Abbott $abbv explain to me why the pricing on LUPRON consistently is raised 10% every year? The drug was approved in 1985 for the love of god - 37 years ago https://t.co/svPbEaTXmI (Twitter) - Dec 6, 2022
- || leuprolide acetate for depot suspension / Generic mfg.
@abbvie has found a new revenue source in transitioning kids, with their drug Lupron. 😖🤯😳 (Twitter) - Dec 2, 2022
- |||||| Yselty (linzagolix) / Kissei, Theramex, Syneos Health
Enrollment open: A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia (clinicaltrials.gov) - Nov 30, 2022
P3, N=264, Recruiting, Sponsor: Kissei Pharmaceutical Co., Ltd.
Future research will focus on enhancing the degree of rational drug use among outpatients and realizing the economical, safe, and effective use of pharmaceuticals to lessen the economic burden of patients. Not yet recruiting --> Recruiting
- |||| Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov) - Nov 29, 2022
P3, N=504, Active, not recruiting, Sponsor: Alliance Foundation Trials, LLC.
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2024 --> Jul 2023
- || Mifeprex (mifepristone) / Danco Laboratories
Retrospective data, Review, Journal: Evaluation of safety and effectiveness of gestrinone in the treatment of endometriosis: a systematic review and meta-analysis. (Pubmed Central) - Nov 27, 2022
Based limited evidence available suggests that gestrinone appeared to be safe and may have some efficacy advantages over danazol, as well as other therapeutic interventions for treating endometriosis. However, this conclusion should be interpreted with caution, due the quality of the evidence provided is generally very low or unclear.
- goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., tamoxifen / Generic mfg.
Ovarian function suppression in early & locally advanced breast cancer: an audit of practice (Exhibition Hall) - Nov 23, 2022 - Abstract #EBCC2022EBCC_371;
Compliance against national guidance has been demonstrated with regards to patient selection for OFS but further work is advised to improve the monitoring and holistic care of these patients, including liaison with primary care. An updated clinical protocol should provide more consistency in the local approach to patients requiring OFS.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Impact of Baseline Testosterone Levels on Relugolix Efficacy and Safety: A Subgroup Analysis from the HERO Study vs Leuprolide in Men with Advanced Prostate Cancer (Sapphire ABEFIJMN) - Nov 20, 2022 - Abstract #SUO2022SUO_184;
In this subgroup analysis, relugolix was effective with a similar safety profile regardless of baseline T levels. These results are consistent with those of the overall population in the HERO study.
- ||| leuprolide acetate for depot suspension / Generic mfg.
Pricing: Another outrageous US medical bill: average wholesale US price for a three-month shot of @abbvie's Lupron: $5,866. In the UK, @Takeda sells a 3 month dose for $260. via @ArthurAllen202 @khn @NPR #BilloftheMonth https://t.co/pqO0zZEB3n (Twitter) - Nov 18, 2022
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Testosterone recovery for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study () - Nov 18, 2022 - Abstract #EMUC2022EMUC_253;
P3
Reused with permission. This abstract was accepted and previously presented at the 2022 Genitourinary Cancers Symposium.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study () - Nov 18, 2022 - Abstract #EMUC2022EMUC_194;
P3
Results for AE onset and duration suggest AEs occur early during treatment with varying duration depending on the type of event. Clinical Trial ID: NCT03085095 This abstract was accepted and previously presented at the 2022 American Urological Association Annual Meeting.
- ||||| enzalutamide capsule / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Clinical, Monotherapy: The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMyWRM @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open (Twitter) - Nov 18, 2022
- | fentanyl citrate / Generic mfg.
Journal: Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating. (Pubmed Central) - Nov 17, 2022
Treatment was administered using bicalutamide and leuprorelin acetate, while a transdermal fentanyl (TDF) was applied for pain relief...For analgesic control, etodolac tablets, carbamazepine tablets, and TDF were administered...When using a TDF, it is necessary to monitor patients for any sweating during treatment, while also considering changes in medication in some cases. This should promote the maintenance and improvement of the quality of life of the affected patients.
- | vancomycin / Generic mfg., morphine sulphate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Journal: Patient characteristics associated with reactions to Mrgprx2-activating drugs in an electronic health record-linked biobank. (Pubmed Central) - Nov 16, 2022
Specific allergic diseases and common allergic biomarkers are differentially associated with ADRs to Mrgprx2-activating drugs. These findings from a large, "real world" drug-exposed population highlight clinical factors that may contribute to non-IgE mediated drug allergy.
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Spawning induction and larval rearing in the thinlip gray mullet (Chelon ramada): The use of the slow release gonadotropin releasing hormone analog (GnRHa) preparation, leuprorelin acetate. (Pubmed Central) - Nov 15, 2022
Present results suggest that mature C. ramada presents easily recognizable reproductive traits, adapts without difficulty to captive conditions, and can be easily induced to spawn administrating a single dose of leuprorelin acetate. The protocol used in our study resulted in high fertilization and hatching rates, as well as promising larval survival minimizing broodstock stress.
- || leuprolide acetate for depot suspension / Generic mfg.
I have considered this case as M1 and would have treated with IGRT to Prostate and pelvic node including involved side of inguinal node after 4-6months of NAHT. Continue Lupron and may add aberaterone (Twitter) - Nov 15, 2022
- | leuprolide acetate for depot suspension / Generic mfg.
Preclinical, Journal: Continuous administration of leuprolide acetate improves urinary function in male rats with severe thoracic spinal cord injury. (Pubmed Central) - Nov 15, 2022
Furthermore, sensory and locomotor responses were also improved in SCI rats. This procedure may have a therapeutic potential to facilitate urinary function recovery in patients with SCI.